BioLineRx (NASDAQ:BLRX) Coverage Initiated at StockNews.com

Investment analysts at StockNews.com began coverage on shares of BioLineRx (NASDAQ:BLRX) in a report released on Monday. The brokerage set a “hold” rating on the biotechnology company’s stock.

Separately, HC Wainwright decreased their price objective on BioLineRx from $21.00 to $9.00 and set a “buy” rating on the stock in a report on Monday, November 25th.

BioLineRx Price Performance

BLRX stock opened at $0.28 on Monday. BioLineRx has a twelve month low of $0.25 and a twelve month high of $1.89. The business’s 50-day simple moving average is $0.45 and its 200 day simple moving average is $0.60. The company has a debt-to-equity ratio of 2.11, a current ratio of 1.52 and a quick ratio of 1.37.

Institutional Trading of BioLineRx

Institutional investors have recently bought and sold shares of the business. PVG Asset Management Corp acquired a new stake in BioLineRx during the 2nd quarter worth $70,000. Atria Investments Inc grew its holdings in BioLineRx by 27.9% during the 3rd quarter. Atria Investments Inc now owns 133,974 shares of the biotechnology company’s stock worth $72,000 after acquiring an additional 29,193 shares during the period. Finally, CVI Holdings LLC acquired a new position in shares of BioLineRx in the 2nd quarter valued at $462,000. Institutional investors and hedge funds own 1.56% of the company’s stock.

BioLineRx Company Profile

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma.